Tideglusib, a non-ATP competitive inhibitor of GSK3β, originally developed for neurodegenerative diseases, exhibits renoprotective effects in DKD models by reducing podocyte damage and oxidative stress through GSK3β modulation (Figure 5D) [43]. This evidence concerns the gene GSK3B and diabetic kidney disease.